Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Raymond James

Raymond James started coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Wednesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $37.00 price target on the stock.

DYN has been the topic of several other research reports. Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Evercore ISI started coverage on shares of Dyne Therapeutics in a report on Thursday, May 29th. They issued an “outperform” rating and a $46.00 target price on the stock. Scotiabank started coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective on the stock. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.93.

Dyne Therapeutics Stock Down 1.4%

Shares of Dyne Therapeutics stock opened at $14.57 on Wednesday. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -4.09 and a beta of 1.17. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The company’s fifty day moving average is $10.90 and its 200 day moving average is $15.44.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, equities analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp raised its holdings in shares of Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after acquiring an additional 698 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after acquiring an additional 721 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 5.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company’s stock worth $237,000 after acquiring an additional 1,115 shares during the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after acquiring an additional 1,249 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock worth $183,000 after acquiring an additional 1,481 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.